Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-QOL: Duloxetine or Furosemide for ET-Induced Pain
NCT06407401Phase 3Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of duloxetine, furosemide in Musculoskeletal pain, sponsored by European Organisation for Research and Treatment of Cancer. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
duloxetinefurosemide
03
Conditions
Musculoskeletal pain
Beyond the preview
Go deeper on NCT06407401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407401.